Opthea Ltd (nasdaq:OPT) Share Price

Company Profile

Business description
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Contact
C/ Prime Company Compliance
505 Little Collins Street, Level 9
MelbourneVIC3000
AUS
T: +61 398260399
https://www.opthea.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
34

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,061.20	61.30	-0.67%
CAC 40	7,853.59	1.02	-0.01%
DAX 40	23,639.41	35.12	-0.15%
Dow JONES (US)	46,315.27	172.85	0.37%
FTSE 100	9,216.67	11.44	-0.12%
HKSE	26,545.10	106.59	0.40%
NASDAQ	22,631.48	160.75	0.72%
Nikkei 225	45,045.81	143.54	0.32%
NZX 50 Index	13,231.66	3.23	-0.02%
S&P 500	6,664.36	32.40	0.49%
S&P/ASX 200	8,773.50	75.00	-0.85%
SSE Composite Index	3,820.09	11.57	-0.30%